Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.57 |
| ▸ | CNR1 | P21554 | 1/20 | 0.56 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | HTR4 | Q13639 | 3/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.36 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4323470 | 0.99 | CNR2 (0.58) | CNR2CNR1MAP3K14TP53HTR4 | |
| SCHEMBL4325990 | 0.97 | CNR2 (0.56) | CNR2CNR1MAP3K14HTR4CSNK2A2 | |
| SCHEMBL13578103 | 0.85 | CNR2 (0.61) | CNR2CNR1HTR4P2RX7 | |
| SCHEMBL13578104 | 0.84 | CNR2 (0.62) | CNR2CNR1HTR4 | |
| SCHEMBL13578182 | 0.83 | CNR2 (0.52) | CNR2CNR1MAP3K14TP53P2RX7 | |
| SCHEMBL13578101 | 0.82 | CNR2 (0.60) | CNR2CNR1HTR4 | |
| SCHEMBL4319869 | 0.81 | CNR2 (0.43) | CNR2CNR1MAP3K14TP53HTR4 | |
| Trifluoroacetic Acid SCHEMBL4319760 | 0.81 | CNR2 (0.57) | CNR2CNR1HTR4L3MBTL1 | |
| SCHEMBL4329126 | 0.81 | HTR4 (0.44) | CNR2CNR1MAP3K14HTR4CSNK2A2 | |
| Trifluoroacetic Acid SCHEMBL4334962 | 0.80 | CNR2 (0.58) | CNR2CNR1HTR4L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | MERCK & CO., INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | MERCK & CO., INC. | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | CNR2, CNR1, TRPV1 | CNR2 1/4885CNR1 2/4885MAP3K14 1432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.